The role of this system in the dynamics of CSF production and absorption is incompletely understood; however , we suggest that proportional upregulation of HSD1 is a compensatory measure to limit existing cortisol deficiencies. absorption. In this integrated mechanism review, we consider the clinical and molecular evidence for each metabolite and hormone in turn. We illustrate how related intracellular signaling cascades may converge in the choroid plexus, drawing on evidence from functionally similar tissues. Pseudotumor cerebri syndrome (PTCS) is defined by the presence of elevated intracranial pressure (ICP) in the setting of normal brain parenchyma and normal cytological and chemical analyses of the cerebrospinal fluid (CSF). Presenting signs and symptoms are varied, particularly in the pediatric GNE 0723 populace, but commonly include headache, visual disturbances (i. e., vision loss or double vision), and papilledema. Patients typically recover with appropriate medical or surgical treatments, but up to 10% of patients may experience permanent visual loss (1). Estimated annual incidence rates of PTCS are 0. 9 per 100, 000 in both the symptomatic pediatric and general adult populations (2, 3). The classification and diagnostic criteria of PTCS have recently been revised in an effort to improve consistency in nomenclature, including distinguishing between apparently primary and secondary (e. g., medication-related) causes (4). The mechanisms underlying PTCS are poorly comprehended (see evaluations (57)); however , the central pathological feature of PTCS is the presence of elevated ICP. Occurring in an enclosed compartment, in the absence of a space-occupying mass, an increase in ICP may be the result of either increased CSF production and/or reduced CSF outflow. Many studies have used advanced neuro-imaging techniques to examine CSF dynamics in PTCS. Many have demonstrated an increased resistance to CSF absorption within the cerebral venous system (8, 9), related to increased cerebral sinus pressure or increased central systemic venous pressure (9), for example. However , questions remain about the family member contributions, and regulation, of accessory CSF outflow routes and the specific site of resistance. Impaired CSF absorption is not likely to explain the pathogenesis of PTCS in its entirety. Rather, there is evidence that primary (obesity-associated) and secondary PTCS may have differing CSF flux disturbances (8). Relevant to focus of the current review, PTCS occurring in the setting of associated endocrinopathies appears to be related to increased CSF production and secondarily raised resistance to CSF absorption (8). As many cases of pediatric PTCS are associated with endocrine or metabolic disorders, this observation may be particularly relevant to this populace. An altered balance of CSF production and absorption is further supported when considering the actions of pharmacologic agents used to lower ICP. Acetazolamide and furosemide reduce CSF production (10). Prednisone is a steroid medication used to lower ICP and manage PTCS at elevated ICPs, prednisone limits CSF production and absorption (11). == A Proposed Integrated Mechanism == We propose that a range of metabolic and hormonal signals regulates CSF dynamics not only by influencing the resistance to CSF absorption but also by acting at the level of the choroid plexus epithelial cells to regulate CSF secretion. The GNE 0723 choroid plexus and its constituent epithelial cells ARF3 are the important site of CSF production and many from the secretory regulatory mechanisms in the choroid plexus are analogous to those within the renal medullary epithelial cells (12). Thus, we further suggest that one way to gain additional novel insights into the mechanisms of PTCS is to translate new insights from renal physiology. PTCS does occur in adult and pediatric patients with renal disease (13) and may complicate management of post-renal-transplant patients, although this observation historically has not been experienced to be a direct association but rather attributed to medication effects or secondary changes in body weight GNE 0723 and/ or hypercoagulability (14). Recent laboratory investigations demonstrate that complementary transporters regulate fluid balance in the kidney and central nervous system (CNS) (seeFigure 1). For example , electro-neutral Na+-HCO3-cotransporters are expressed in the medullary collecting duct epithelial cells from the kidney, as well as the epithelial cells of the choroid plexus in the CNS (12). Studies in animals engineered to lack these important transporters (15) lend additional support to this contention. Knock-out of the SCL4 family of bicarbonate transporter leads to reduced brain ventricle size, perhaps due to decreased CSF production (15). Carbonic anhydrase inhibitors influence the activity of this transporter system (seeFigure 1) and are effective in the treatment of patients with PTCS (10). Finally, mice lacking aquaporin-1 (AQP, seeFigure 1), another important water transport channel, also had reduced ICP and CSF production (15). Specifically, we hypothesize that in patients with PTCS, mitochondrial metabolites (glutamate and succinate), along with insulin, and steroid hormones (cortisol, 11-deoxycortisol, aldosterone, 11-deoxycorticosterone; see below),.